Loading
Adipokines, Inflammation, and Metabolic Diseases · Journal article
Journal of Nanobiotechnology · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical proof-of-concept study in obese mice demonstrating that an injectable hydrogel system delivering ursolic acid in mesoporous polydopamine nanoparticles, combined with mild photothermal therapy, reduces body weight and fat mass while improving metabolic markers. The work is mechanistically interesting but lacks human efficacy data, controlled trial design transparency, and independent replication necessary to establish clinical utility.
Preclinical in vivo study in obese mice with in vitro mechanistic validation. Obese mice; adipocyte cultures for mechanistic studies.. Intervention: Injectable OCMU hydrogel (oxidized hyaluronic acid and carboxymethyl chitosan) loaded with ursolic acid in mesoporous polydopamine nanoparticles, combined with mild photothermal therapy (PTT).. Compared with: Monotherapies (PTT alone or ursolic acid alone implied by text); no explicit control group design provided..
OCMU hydrogel achieved 81.04% ursolic acid loading capacity In vitro: 439% increase in UCP1 expression via AMPK/SIRT1/PGC-1α pathway activation In obese mice: OCMU with photothermal therapy reduced body weight by 10.94%
Safety profile described only as 'favorable' without quantitative adverse event data.
This work remains at the discovery stage and does not yet warrant clinical application. Clinicians should await human phase 1/2 data demonstrating safety and dose-response before considering therapeutic potential.
Preclinical study in obese mice demonstrating proof-of-concept for a novel nanoparticle-hydrogel system; lacks human data, clinical endpoints, and peer-reviewed publication evidence in the provided text.
As stated by the source record.
Quoted from the source exactly as published.
This work remains at the discovery stage and does not yet warrant clinical application. Clinicians should await human phase 1/2 data demonstrating safety and dose-response before considering therapeutic potential.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Obesity and its metabolic complications urgently require safe, effective, and minimally invasive interventions. Here, we engineered an injectable, self-healing hydrogel system (OCMU hydrogel) based on oxidized hyaluronic acid (OHA) and carboxymethyl chitosan (CMCS) for the localized delivery of plant-based ursolic acid (UA) loaded in mesoporous polydopamine (MPDA) nanoparticles. This system synergistically induces white adipose browning through combined photothermal therapy (PTT) and pharmacological action, effectively counteracting obesity. The OCMU hydrogel exhibited excellent self-healing properties, high UA loading capacity (81.04%), efficient photothermal conversion, and favorable biocompatibility. Mechanistically, the system promotes lipolysis, mitochondrial biogenesis, and adipose browning via activation of the AMPK/SIRT1/PGC-1α pathway, with a 439% increase in UCP1 expression in vitro. In obese mice, OCMU combined with PTT reduced body weight by 10.94% and inguinal fat by 56.32%, while significantly improving metabolic profiles and alleviating inflammation. Notably, the combination of mild PTT and naturally derived UA achieved superior anti-obesity efficacy compared to monotherapies, highlighting a favorable safety and efficacy profile. This work establishes a promising platform in which UA and mild PTT act in concert to reprogram adipocyte metabolism, offering a safe and synergistic approach to combat obesity.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.